ABMD - Abiomed posts Q4 topline beat provides 2022 forecast

Abiomed (ABMD) posted fourth-quarter revenue that beat Wall Street estimates, helped by rising demand for its Impella heart pump worldwide.Worldwide Impella heart pump revenue for the quarter increased 17% to $230.4M.The company posted quarterly revenue of $241.2M compared to $206.7M for the same period last year. Analysts were expecting $231.13M.Gross margin in the quarter was 80.9%, flat compared to the same period of fiscal 2020.As of March 31, 2021, the company had $847.8M of cash and marketable securities and no debt.Fourth quarter net income was $56.9M, or $1.24 per share, compared to $31.8M, or $0.70 per share last year.The company expects 2022 global revenue to be in the range of $990M to $1,030M, representing 17% to 22% growth compared to this year.Abiomed also expects GAAP operating margin to be in the range of 24% to 26%.Previously (April 29): Abiomed EPS misses by $0.06, beats on revenue.

For further details see:

Abiomed posts Q4 topline beat, provides 2022 forecast